Hubungan Kepatuhan Terapi Dengan Kontrol Glikemik Peserta Prolanis Pasien Diabetes Mellitus Tipe 2 di Puskesmas Prambanan Sleman

Amaliyah Nur Khasanah (Fakultas Kedokteran dan Ilmu-Ilmu Kesehatan, Universitas Alma Ata, Jalan Brawijaya Nomor 99, Yogyakarta, 55183, Daerah Istimewa Yogyakarta, Indonesia)
RA Dewinta Sukma Ananda (Fakultas Kedokteran dan Ilmu-Ilmu Kesehatan, Universitas Alma Ata, Jalan Brawijaya Nomor 99, Yogyakarta, 55183, Daerah Istimewa Yogyakarta, Indonesia)
Eva Nurinda (Fakultas Kedokteran dan Ilmu-Ilmu Kesehatan, Universitas Alma Ata, Jalan Brawijaya Nomor 99, Yogyakarta, 55183, Daerah Istimewa Yogyakarta, Indonesia)
Ari Susiana Wulandari (Fakultas Kedokteran dan Ilmu-Ilmu Kesehatan, Universitas Alma Ata, Jalan Brawijaya Nomor 99, Yogyakarta, 55183, Daerah Istimewa Yogyakarta, Indonesia)

Jurnal Farmasi Galenika
Vol 13 No 2 (2026): August 2026 (In Press)

Diabetes Mellitus (DM) is one of the four non-communicable diseases categorized as a top priority, requiring long-term management to prevent serious complications. Glycemic control is a critical factor in managing the disease, yet medication non-adherence remains a significant challenge. The Chronic Disease Management Program (Prolanis) aims to optimize participants' quality of life via BPJS Kesehatan (National Health Insurance provider). This study aimed to determine the relationship between therapeutic adherence and glycemic control among Type 2 Diabetes Mellitus (T2DM) Prolanis participants at the Prambanan Public Health Center, Sleman. This observational study employed a cross-sectional design and included 34 participants who met the inclusion and exclusion criteria. The results indicated that the majority of participants—21 individuals (61.8%)—were non-adherent to therapy, with 12 of them (57.1%) having uncontrolled glycemic levels. Among the 13 participants (38.2%) who adhered to therapy, 11 (84.6%) achieved controlled glycemic levels. There was an association between therapeutic adherence and glycemic control in T2DM Prolanis participants at the Prambanan Public Health Center, Sleman.